Literature DB >> 11606125

Synthesis and antitumor activity of conjugates of muramyldipeptide, normuramyldipeptide, and desmuramylpeptides with acridine/acridone derivatives.

K Dzierzbicka1, A M Kołodziejczyk, B Wysocka-Skrzela, A Myśliwski, D Sosnowska.   

Abstract

The synthesis of two groups (Chart 1, types A and B) of conjugates of MDP (muramyldipeptide) and nor-MDP (normuramyldipeptide) with acridine/acridone derivatives and the synthesis of analogues of desmuramylpeptides (Chart 1, types C and D) containing acridine/ acridone derivatives have been described. In type A conjugates, the hydroxyl group at C6 of the sugar moiety was acylated with acridine/acridone N-substituted omega-aminoalkanocarboxylic acids (Scheme 1), whereas the conjugates of type B (Table 2) and three analogues of type C or D (Scheme 2) have an amide bond formed between the carboxylic group of isoglutamine and the amine function of the respective acridine/acridone derivatives. The preliminary screening data indicate that the analogues of groups A, C, and D exhibit small cytotoxic activity, whereas several analogues of type B, 4b, 4c, 4e, 4g, 4h, 4i, and 4l, exhibiting potent in vitro cytotoxic activity against a panel of human cell lines (Table 4), have been selected by the National Cancer Institute (NCI) Evaluation Committee for further testing. Analogues 4b and 4h were active in the in vivo hollow fiber assay (Table 5). Analogue 3a shows an immunostimulating effect on the cytotoxic activity of the NK cells obtained from the spleen of healthy and Ab melanoma bearing animals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606125     DOI: 10.1021/jm001115g

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Design, synthesis, in vitro cytotoxic activity evaluation, and apoptosis-induction study of new 9(10H)-acridinone-1,2,3-triazoles.

Authors:  Maryam Mohammadi-Khanaposhtani; Maliheh Safavi; Reyhaneh Sabourian; Mohammad Mahdavi; Mahboobeh Pordeli; Mina Saeedi; Sussan Kabudanian Ardestani; Alireza Foroumadi; Abbas Shafiee; Tahmineh Akbarzadeh
Journal:  Mol Divers       Date:  2015-07-14       Impact factor: 2.943

2.  Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy.

Authors:  Chikako Ogawa; Yuen-Joyce Liu; Koichi S Kobayashi
Journal:  Curr Bioact Compd       Date:  2011-09

Review 3.  Use of the in vivo hollow fiber assay in natural products anticancer drug discovery.

Authors:  Qiuwen Mi; John M Pezzuto; Norman R Farnsworth; Mansukh C Wani; A Douglas Kinghorn; Steven M Swanson
Journal:  J Nat Prod       Date:  2009-03-27       Impact factor: 4.050

4.  10-(4-Chloro-phen-yl)-9-(4-fluoro-phen-yl)-3,3,6,6-tetra-methyl-3,4,6,7,9,10-hexa-hydro-acridine-1,8(2H,5H)-dione.

Authors:  Ling-Ling Zhao; Da Teng
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-08-16

Review 5.  Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy.

Authors:  Sanja Nabergoj; Irena Mlinarič-Raščan; Žiga Jakopin
Journal:  Med Res Rev       Date:  2018-12-13       Impact factor: 12.944

6.  Novel therapeutic compound acridine-retrotuftsin action on biological forms of melanoma and neuroblastoma.

Authors:  Miroslawa Cichorek; Anna Ronowska; Monika Gensicka-Kowalewska; Milena Deptula; Iwona Pelikant-Malecka; Krystyna Dzierzbicka
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-26       Impact factor: 4.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.